Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

BACKGROUND: The cardiovascular (CV) safety of linagliptin was evaluated in subjects with type 2 diabetes (T2DM). METHODS: Pre-specified patient-level pooled analysis of all available double-blind, randomized, controlled trials, ≥12 weeks’ duration (19 trials, 9459 subjects) of linagliptin versus pla...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cardiovasc Diabetol
Главные авторы: Rosenstock, Julio, Marx, Nikolaus, Neubacher, Dietmar, Seck, Thomas, Patel, Sanjay, Woerle, Hans-Juergen, Johansen, Odd Erik
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2015
Предметы:
Original Investigation
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4465456/
https://ncbi.nlm.nih.gov/pubmed/25990013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-015-0215-2
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы